New York, NYNCT06892288Now EnrollingIRB Ready

PMM2-CDG Clinical Trial in New York, NY

Access cutting-edge pmm2-cdg treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Glycomine, Inc.

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions...

Expert Care in New York

Access pmm2-cdg specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pmm2-cdg treatment provided free

Apply for This New York Location

Check if you qualify for this pmm2-cdg clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This PMM2-CDG Study in New York

This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including children, adolescents, and adults. Researchers will compare participants receiving GLM101 to those receiving a placebo to see if GLM101 improves symptoms of PMM2-CDG. The study includes two treatment parts: a 24-week double blind placebo-controlled treatment period (Part A), and a 24-week open-label phase where every participant will receive

Sponsor: Glycomine, Inc.

Who Can Participate

Inclusion Criteria

Participant is eligible for participation in the study if all of the following apply:
Participant is aged ≥ 4 years old at the time of signing the consent.
Participant with molecular diagnosis of PMM2-CDG. Diagnosis is defined as biallelic pathogenic and/or likely pathogenic variants, or, in the case of variants of uncertain pathogenicity, demonstration of biallelic variants and PMM2 enzyme activity consistent with a diagnosis of PMM2-CDG. Diagnosis with laboratory report(s) on file is required.
Participant is willing and capable of completing the ICARS in its entirety without any assessment deemed as "not evaluable".
Participant screening total ICARS score is ≥ 20 and ≤ 80 .
Male or female participant has appropriate measures in place to prevent pregnancy:
If the participant is a woman of childbearing potential, i.e., fertile, following menarche and until becoming postmenopausal unless permanently sterile (permanent sterilization methods include hys

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT06892288) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

PMM2-CDG Treatment Options in New York, NY

If you're searching for pmm2-cdg treatment options in New York, NY, this clinical trial (NCT06892288) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pmm2-cdg specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pmm2-cdg clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in New York, NY

See all multiple myeloma clinical trials recruiting in New York — not just this study.

Browse Multiple Myeloma Trials in New York →

Browse More Trials by Condition

Multiple Myeloma TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY